Drug profile

The FDA adverse-event record for Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp

403 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp. See the species affected, top reactions, and outcomes below.

403
adverse-event reports
1.2%
death-coded share
Dog
most-reported species
313
Deafness - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
403
Total Reports
5
Deaths Reported
1.2%
Death Rate

Active Ingredients

Betamethasone Valerate, UspClotrimazole, UspGentamicin Sulfate, Usp

Administration Routes

Auricular (Otic)UnknownTopicalIntradermalTransdermal

Species Affected

Dog 393
Cat 7
Unknown 3

Most Affected Breeds

Unknown 80
Retriever - Labrador 34
Terrier - Yorkshire 17
Chihuahua 14
Boxer (German Boxer) 12
Pug 12
Pit Bull 12
Terrier - West Highland White 11
Retriever - Golden 10
Shepherd Dog - German 9

Most Reported Reactions

Deafness 313
PR-EAR(S), LESION(S) 47
Partial deafness 17
Loss of hearing 16
Hearing affected 13
Hearing decreased 7
Temporary deafness 7
Impaired hearing 5
Vomiting 4
Anorexia 3
Skin irritation 3
Diarrhoea 2

Outcome Breakdown

Ongoing
202 (52.2%)
Outcome Unknown
125 (32.3%)
Recovered/Normal
48 (12.4%)
Recovered with Sequela
7 (1.8%)
Euthanized
3 (0.8%)
Died
2 (0.5%)

Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp Adverse Event Insights

403 reports name Betamethasone Valerate, Usp + Clotrimazole, Usp + Gentamicin Sulfate, Usp; 5 recorded a death outcome (1.2% of reported events, not a population-level mortality rate). Active ingredients: Betamethasone Valerate, Usp, Clotrimazole, Usp, Gentamicin Sulfate, Usp. Administration routes: Auricular (Otic), Unknown, Topical, Intradermal.

By species: Dog (393 reports), Cat (7 reports), Unknown (3 reports). By breed: Unknown (80), Retriever - Labrador (34), Terrier - Yorkshire (17).

Leading clinical signs: Deafness (313), PR-EAR(S), LESION(S) (47), Partial deafness (17), Loss of hearing (16). Outcome, 387 coded reports: Ongoing leads at 52.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.